arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Pulmatrix, Inc.

PULM
$1.67 ▼ -0.07 (-4.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pulmatrix, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -107.2%
FCF / Share $-1.49
Trailing P/E
Price / Book 1.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.81M
↑ +7.0%
Net Income Profit after all expenses
$-5.16M
↑ +46.0%
Operating Margin Operating profit as % of sales
-125.1%
↑ +38.1%
FCF / Share Free cash flow per share
$-1.49
↑ +51.1%
Long-Term Debt Long-term obligations
$3.22M
↓ -43.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters